#Precigen is proud to announce the first and only @US_FDA-approved therapy for the treatment of adults with #RecurrentRespiratoryPapillomatosis. View press release:

RT @NIH: NIH is thrilled to announce that the @US_FDA has granted full market approval for Papzimeos, a groundbreaking immunotherapy for ad….

RT @US_FDA: Today, we approved a first-of-its-kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patient….

Join us on Wednesday, September 18 for a fireside chat with @Precigen's President and CEO, Helen Sabzevari, at the 2024 Cantor Global Healthcare Conference. View details and register for the webcast: #CantorHCC

@Precigen reports second quarter / first half 2024 financial results and business updates. View press release and join our conference call today at 4:30pm ET: $PGEN

Join #Precigen on Wednesday, August 14, 2024 at 4:30 PM ET for a conference call to discuss second quarter and first half 2024 financial results. View details: $PGEN

#ICYMI: Watch the replay and check out photos from the first #RRPAwarenessDay. Thank you to our patient and caregiver panelists, our co-hosts at RRPF, @theNCI panelists, @MarkWarner, @iamwesmoore and all who viewed the event! #GivingVoicetoInspireChange

We had an amazing time at our inaugural #RRPAwarenessDay. Together, we are shaping a hopeful and positive future for those impacted by RRP. Watch the #RRPAwarenessDay co-hosts share their thoughts on what they hope we achieved for RRP patients today. #GivingVoicetoInspireChange

Only 1 week to go until RRP Awareness Day, a multi-stakeholder event to raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials. View details at and join us!

@Precigen is excited to announce pivotal study results for PRGN-2012 in RRP presented today in a late-breaking oral presentation at #ASCO24. Join us today for a live webcast with Precigen executives and study lead investigators. View data:

#ASCO24: On Monday, June 3, check out the trial-in-progress poster for @Precigen's PRGN-2009 AdenoVerse Gene Therapy in recurrent or metastatic cervical cancer (Abstract # TPS5623). #GeneTherapy #Oncology #ClinicalTrials #CervicalCancer #OncoAlert

#ASCO24: On Sunday, June 2, check out the trial-in-progress poster for @Precigen's PRGN-2009 AdenoVerse Gene Therapy in HPV-associated oropharyngeal cancer (Abstract# TPS6124). #GeneTherapy #Oncology #ClinicalTrials #OncoAlert

#Precigen to host a webcast on June 3 at 6:00 PM CT following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of RRP at #ASCO24. View details: $PGEN

Congratulations to #Precigen President and CEO, Helen Sabzevari, for being named as a PM360 Elite100 honoree in the Drug Researchers and Developers category. We are proud of her extraordinary leadership to advance innovative medicines.

@Precigen reports first quarter 2024 financial results and business updates. View press release: $PGEN